Table of Contents Author Guidelines Submit a Manuscript
Schizophrenia Research and Treatment
Volume 2014 (2014), Article ID 602390, 7 pages
http://dx.doi.org/10.1155/2014/602390
Research Article

Polyphenols from Berries of Aronia melanocarpa Reduce the Plasma Lipid Peroxidation Induced by Ziprasidone

1Department of Biological Psychiatry, The Chair of Experimental and Clinical Physiology, Medical University of Lodz, 6/8 Mazowiecka Street, 92-215 Lodz, Poland
2Department of General Biochemistry, Faculty of Biology and Environmental Protection, University of Lodz, 90-236 Lodz, Poland

Received 23 March 2014; Revised 21 May 2014; Accepted 26 May 2014; Published 25 June 2014

Academic Editor: Robin Emsley

Copyright © 2014 Anna Dietrich-Muszalska et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H.-G. Bernstein, B. Bogerts, and G. Keilhoff, “The many faces of nitric oxide in schizophrenia: a review,” Schizophrenia Research, vol. 78, no. 1, pp. 69–86, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Dietrich-Muszalska and B. Olas, “Isoprostenes as indicators of oxidative stress in schizophrenia,” World Journal of Biological Psychiatry, vol. 10, no. 1, pp. 27–33, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Dietrich-Muszalska, B. Olas, and J. Rabe-Jablonska, “Oxidative stress in blood platelets from schizophrenic patients,” Platelets, vol. 16, no. 7, pp. 386–391, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. H.-C. Li, Q.-Z. Chen, Y. Ma, and J.-F. Zhou, “Imbalanced free radicals and antioxidant defense systems in schizophrenia: a comparative study,” Journal of Zhejiang University Science B, vol. 7, no. 12, pp. 981–986, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. R. D. Reddy and J. K. Yao, “Free radical pathology in schizophrenia: a review,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 55, no. 1-2, pp. 33–43, 1996. View at Google Scholar · View at Scopus
  6. N. Srivastava, M. K. Barthwal, P. K. Dalal et al., “Nitrite content and antioxidant enzyme levels in the blood of schizophrenia patients,” Psychopharmacology, vol. 158, no. 2, pp. 140–145, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. J. K. Yao and M. S. Keshavan, “Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view,” Antioxidants and Redox Signaling, vol. 15, no. 7, pp. 2011–2035, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. J. K. Yao, R. Reddy, L. G. Mcelhinny, and D. P. van Kammen, “Reduced status of plasma total antioxidant capacity in schizophrenia,” Schizophrenia Research, vol. 32, no. 1, pp. 1–8, 1998. View at Publisher · View at Google Scholar · View at Scopus
  9. J. K. Yao, R. D. Reddy, L.G. Mcelhinny, and D. P. van Kammen, “Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications,” CNS Drugs, vol. 15, no. 4, pp. 287–310, 2001. View at Google Scholar · View at Scopus
  10. N. G. Gomes, M. G. Campos, J. M. Orfão, and C. A. Ribeiro, “Plants with neurobiological activity as potential targets for drug discovery,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 33, no. 8, pp. 1372–1389, 2009. View at Google Scholar
  11. D. F. Horrobin, “Schizophrenia as a membrane lipid disorder which is expressed throughout the body,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 55, no. 1-2, pp. 3–7, 1996. View at Google Scholar · View at Scopus
  12. D. P. van Kammen, J. K. Yao, and K. Goetz, “Polyunsaturated fatty acids, prostaglandins, and schizophrenia,” Annals of the New York Academy of Sciences, vol. 559, pp. 411–423, 1989. View at Google Scholar · View at Scopus
  13. D. F. Horrobin, M. S. Manku, H. Hillman, A. Iain, and M. Glen, “Fatty acid levels in the brains of schizophrenics and normal controls,” Biological Psychiatry, vol. 30, no. 8, pp. 795–805, 1991. View at Publisher · View at Google Scholar · View at Scopus
  14. J. K. Yao, S. Leonard, and R. D. Reddy, “Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients,” Schizophrenia Research, vol. 42, no. 1, pp. 7–17, 2000. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Kunz, C. S. Gama, A. C. Andreazza et al., “Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 32, no. 7, pp. 1677–1681, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Kedzierska, B. Olas, B. Wachowicz et al., “An extract from berries of Aronia melanocarpa modulates the generation of superoxide anion radicals in blood platelets from breast cancer patients,” Planta Medica, vol. 75, no. 13, pp. 1405–1409, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. V. Parikh, M. M. Khan, and S. P. Mahadik, “Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain,” Journal of Psychiatric Research, vol. 37, no. 1, pp. 43–51, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Pillai, V. Parikh, A. V. Terry Jr., and S. P. Mahadik, “Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain,” Journal of Psychiatric Research, vol. 41, no. 5, pp. 372–386, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Zhang, Z. Zhao, L. He, and C. Wan, “A meta-analysis of oxidative stress markers in schizophrenia,” Science China Life Sciences, vol. 53, no. 1, pp. 112–124, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. A. O. Skinner, S. P. Mahadik, and D. L. Garver, “Thiobarbituric acid reactive substances in the cerebrospinal fluid in schizophrenia,” Schizophrenia Research, vol. 76, no. 1, pp. 83–87, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Peet, J. Laugharne, N. Rangarajan, and G. P. Reynolds, “Tardive dyskinesia, lipid peroxidation, and sustained amelioration with vitamin E treatment,” International Clinical Psychopharmacology, vol. 8, no. 3, pp. 151–153, 1993. View at Google Scholar · View at Scopus
  22. J. B. Lohr, R. Kuczenski, H. S. Bracha, M. Moir, and D. V. Jeste, “Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia,” Biological Psychiatry, vol. 28, no. 6, pp. 535–539, 1990. View at Publisher · View at Google Scholar · View at Scopus
  23. H. S. Pall, A. C. Williams, D. R. Blake, and J. Lunec, “Evidence of enhanced lipid peroxidation in the cerebrospinal fluid of patients taking phenothiazines,” The Lancet, vol. 2, no. 8559, pp. 596–599, 1987. View at Google Scholar · View at Scopus
  24. G. Tsai, D. C. Goff, R. W. Chang, J. Flood, L. Baer, and J. T. Coyle, “Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia,” The American Journal of Psychiatry, vol. 155, no. 9, pp. 1207–1213, 1998. View at Google Scholar · View at Scopus
  25. G. Bjelakovic, D. Nikolova, L. L. Gluud, R. G. Simonetti, and C. Gluud, “Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases,” Cochrane Database of Systematic Reviews, vol. 3, Article ID CD007176, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. G. Bjelakovic, D. Nikolova, and C. H. Gluud, “Meta-regression analyses, meta-analyses, and trial sequential analyses of the effects of supplementation with beta-carotene, vitamin A, and vitamin E singly or in different combinations on all-cause mortality: do we have evidence for lack of harm?” PLoS ONE, vol. 8, no. 9, Article ID e74558, 2013. View at Google Scholar
  27. S. Eilat-Adar, T. Sinai, C. Yosefy, and Y. Henkin, “Nutritional recommendations for cardiovascular disease prevention review,” Nutrients, vol. 5, no. 9, pp. 3646–3683, 2013. View at Publisher · View at Google Scholar
  28. L. Hooper, P. A. Kroon, E. B. Rimm et al., “Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials,” The American Journal of Clinical Nutrition, vol. 88, no. 1, pp. 38–50, 2008. View at Google Scholar · View at Scopus
  29. R. Reddy, M. P. Sahebarao, S. Mukherjee, and J. N. Murthy, “Enzymes of the antioxidant defense system in chronic schizophrenic patients,” Biological Psychiatry, vol. 30, no. 4, pp. 409–412, 1991. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Dietrich-Muszalska and B. Kontek, “Lipid peroxidation in patients with schizophrenia,” Psychiatry and Clinical Neurosciences, vol. 64, no. 5, pp. 469–475, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. C. S. Gama, M. Salvador, A. C. Andreazza, F. Kapczinski, and P. Silva Belmonte-de-Abreu, “Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: a study of patients treated with haloperidol or clozapine,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 30, no. 3, pp. 512–515, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. I. Jeding, P. J. Evans, D. Akanmu et al., “Characterization of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs,” Biochemical Pharmacology, vol. 49, no. 3, pp. 359–365, 1995. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Dietrich-Muszalska, B. Kontek, and J. Rabe-Jabłońska, “Quetiapine, olanzapine and haloperidol affect human plasma lipid peroxidation in vitro,” Neuropsychobiology, vol. 63, no. 4, pp. 197–201, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Dietrich-Muszalska, J. Kopka, and A. Kwiatkowska, “The effects of ziprasidone, clozapine and haloperidol on lipid peroxidation in human plasma (in vitro): comparison,” Neurochemical Research, vol. 38, no. 7, pp. 1490–1495, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Dietrich-Muszalska, “Evaluation of the effects of different concentrations of risperidone, corresponding to the drug doses used in treatment of schizophrenic patients, on lipid peroxidation in plasma and blood platelets at in vitro studies,” PsychIatria I PsychologIa Kliniczna, vol. 4, no. 4, pp. 215–223, 2004. View at Google Scholar
  36. A. Dietrich-Muszalska and B. Olas, “Inhibitory effects of polyphenol compounds on lipid peroxidation caused by antipsychotics (haloperidol and amisulpride) in human plasma in vitro,” World Journal of Biological Psychiatry, vol. 11, no. 2, pp. 276–281, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. Y. Sagara, “Induction of reactive oxygen species in neurons haloperidol,” Journal of Neurochemistry, vol. 71, no. 3, pp. 1002–1012, 1998. View at Google Scholar · View at Scopus
  38. S. Chung, H. Yao, S. Caito, J.-W. Hwang, G. Arunachalam, and I. Rahman, “Regulation of SIRT1 in cellular functions: role of polyphenols,” Archives of Biochemistry and Biophysics, vol. 501, no. 1, pp. 79–90, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. B. Olas, M. Kedzierska, B. Wachowicz, A. Stochmal, and W. Oleszek, “Effects of polyphenol-rich extract from berries of Aronia melanocarpa on the markers of oxidative stress and blood platelet activation,” Platelets, vol. 21, no. 4, pp. 274–281, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. A. F. Schatzberg and C. B. Nemeroff, Eds., The American Psychiatric Publishing Textbook of Psychopharmacology, American Psychiatric Publishing, Arlington, Va, USA, 2004.
  41. E. Stip, S. Zhornitsky, H. Moteshafi et al., “Ziprasidone for psychotic disorders: a meta-analysis and systematic review of the relationship between pharmacokinetics, pharmacodynamics, and clinical profile,” Clinical Therapeutics, vol. 33, no. 12, pp. 1853–1867, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. D. V. Sheehan, Y. Lecrubier, K. H. Sheehan et al., “The mini-international neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10,” Journal of Clinical Psychiatry, vol. 59, supplement 20, pp. 22–33, 1998. View at Google Scholar · View at Scopus
  43. C. A. Rice-Evans, A. T. Diplock, and M. C. Symons, Techniques in Free Radical Research, Elsevier, New York, NY, USA, 1991.
  44. B. Wachowicz and J. Kustron, “Effect of cisplatin on lipid peroxidation in pig blood platelets,” Cytobios, vol. 70, pp. 41–47, 1992. View at Google Scholar
  45. S. P. Machadik, S. Mukherjee, R. Scheffer, E. E. Correnti, and J. S. Mahadik, “Elevated plasma lipid peroxides at the onset of nonaffective psychosis,” Biological Psychiatry, vol. 43, no. 9, pp. 674–679, 1998. View at Publisher · View at Google Scholar · View at Scopus
  46. R. G. McCreadie, E. MacDonald, D. Wiles, G. Campbell, and J. R. Paterson, “The nithsdale schizophrenia surveys. XIV: plasma lipid peroxide and serum vitamin E levels in patients with and without tardive dyskinesia, and in normal subjects,” The British Journal of Psychiatry, vol. 167, no. 5, pp. 610–617, 1995. View at Google Scholar · View at Scopus
  47. A. Dietrich-Muszalska and B. Olas, “Modifications of blood platelet proteins of patients with schizophrenia,” Platelets, vol. 20, no. 2, pp. 90–96, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Dietrich-Muszalska, B. Olas, R. Głowacki, and E. Bald, “Oxidative/nitrative modifications of plasma proteins and thiols from patients with schizophrenia,” Neuropsychobiology, vol. 59, no. 1, pp. 1–7, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. D. Taylor, C. Paton, and R. Kerwin, The South London and Maudsley NHS Trust. Prescribing Guidelines, Martin Dunitz, Taylor & Francis, London, UK, 7th edition, 2003.
  50. P. S. Naidu and S. K. Kulkarni, “Quercefin, a bioflavonoid, reverses haloperidol-induced catalepsy,” Methods and Findings in Experimental and Clinical Pharmacology, vol. 26, no. 5, pp. 323–326, 2004. View at Publisher · View at Google Scholar · View at Scopus
  51. B. Olas and B. Wachowicz, “Resveratrol, a phenolic antioxidant with effects on blood platelet functions,” Platelets, vol. 16, no. 5, pp. 251–260, 2005. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Bijak, M. Bobrowski, M. Borowiecka, A. Podsȩdek, J. Golański, and P. Nowak, “Anticoagulant effect of polyphenols-rich extracts from black chokeberry and grape seeds,” Fitoterapia, vol. 82, no. 6, pp. 811–817, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. M. Naruszewicz and M. Dluzniewski, “Flavonoids from choheberry fruits (Aronia melanocarpa) reduce oxidative stress and inflammation in patients with coronary artery disease treated with statins (Short lectures),” Planta Medica, vol. 73, 2007. View at Google Scholar
  54. X. F. Li, Y. L. Zheng, M. H. Xiu, D. C. Chen, T. R. Kosten, and X. Y. Zhang, “Reduced plasma total antioxidant status in first-episode drug-naive patients with schizophrenia,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 35, no. 4, pp. 1064–1067, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. J. K. Yao, R. Reddy, and D. P. van Kammen, “Abnormal age-related changes of plasma antioxidant proteins in schizophrenia,” Psychiatry Research, vol. 97, no. 2-3, pp. 137–151, 2000. View at Publisher · View at Google Scholar · View at Scopus
  56. M. Raffa, F. Atig, A. Mhalla, A. Kerkeni, and A. Mechri, “Decreased glutathione levels and impaired antioxidant enzyme activities in drug-naive first-episode schizophrenic patients,” BMC Psychiatry, vol. 11, article 124, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. S. Grignon and J. M. Chianetta, “Assessment of malondialdehyde levels in schizophrenia: a meta-analysis and some methodological considerations,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 31, no. 2, pp. 365–369, 2007. View at Publisher · View at Google Scholar · View at Scopus
  58. B. M. Al-Chalabi, I. A. J. Thanoon, and F. A. Ahmed, “Potential effect of olanzapine on total antioxidant status and lipid peroxidation in schizophrenic patients,” Neuropsychobiology, vol. 59, no. 1, pp. 8–11, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. G. Dadheech, S. Mishra, S. Gautam, and P. Sharma, “Evaluation of antioxidant deficit in schizophrenia,” Indian Journal of Psychiatry, vol. 50, no. 1, pp. 16–20, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. M. Padurariu, A. Ciobica, I. Dobrin, and C. Stefanescu, “Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics,” Neuroscience Letters, vol. 479, no. 3, pp. 317–320, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. S. Kropp, V. Kern, K. Lange et al., “Oxidative stress during treatment with first- and second-generation antipsychotics,” Journal of Neuropsychiatry and Clinical Neurosciences, vol. 17, no. 2, pp. 227–231, 2005. View at Publisher · View at Google Scholar · View at Scopus